Stock GILD GILEAD SCIENCES, INC.
Add to a list

ETFs Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 16:00:00 2026-02-12 EST 		5-day change 1st Jan Change
151.81 USD -2.56% Intraday chart for Gilead Sciences, Inc. +1.63% +23.68%
04:20am China Medical University Hospital Collaborates with Ever Supreme Bio Technology to Develop Exosome Platform CI
02-12 Wolfe Adjusts Price Target on Gilead Sciences to $170 From $155, Maintains Outperform Rating MT

ETFs positioned on Gilead Sciences, Inc.

Name Varia. Jan 1. Weight AuM
AGF U.S. MARKET NEUTRAL ANTI-BETA FUND - USD ETF AGF U.S. Market Neutral Anti-Beta Fund - USD
-1.81%13.99% 253 M€
FIRST TRUST NYSE ARCA BIOTECHNOLOGY ETF - CAD ETF First Trust NYSE Arca Biotechnology ETF - CAD
0.00%3.55% 1 M€
FRANKLIN U.S. LOW VOLATILITY HIGH DIVIDEND INDEX ETF - USD ETF Franklin U.S. Low Volatility High Dividend Index ETF - USD
+9.57%2.9% 484 M€
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY ETF Nomura NEXT FUNDS International Equity MSCI-KOKUSAI (Yen-Hedged) ETF - JPY
-0.48%2.66% 26 M€
VANECK MORNINGSTAR US ESG WIDE MOAT UCITS ETF - USD ETF VanEck Morningstar US ESG Wide Moat UCITS ETF - USD
-0.57%2.62% 324 M€
FIRST TRUST MORNINGSTAR DIVIDEND LEADERS ETF (CAD-HEDGED) - CAD ETF First Trust Morningstar Dividend Leaders ETF (CAD-Hedged) - CAD
0.00%2.58% 6 M€
FIRST TRUST ALPHADEX U.S. HEALTH CARE SECTOR INDEX ETF - CAD HEDGED ETF First Trust AlphaDEX U.S. Health Care Sector Index ETF - CAD Hedged
-.--%2.27% 2 M€
FIRST TRUST ALPHADEX U.S. HEALTH CARE SECTOR INDEX ETF - CAD ETF First Trust AlphaDEX U.S. Health Care Sector Index ETF - CAD
-.--%1.26% 4 M€
HARTFORD DISCIPLINED US EQUITY ETF - USD ETF Hartford Disciplined US Equity ETF - USD
+0.57%1.16% 132 M€
VICTORYSHARES US EQ INCOME ENHANCED VOLATILITY WTD ETF - USD ETF VictoryShares US EQ Income Enhanced Volatility Wtd ETF - USD
+10.61%1.04% 615 M€
DIREXION NASDAQ-100 EQUAL WEIGHTED ETF - USD ETF Direxion NASDAQ-100 Equal Weighted ETF - USD
-0.77%1.01% 1,034 M€
LEVERAGE SHARES -5X SHORT NASDAQ 100 ETP - USD ETF Leverage Shares -5x Short Nasdaq 100 ETP - USD
+10.47%0.98% 5 M€
LEVERAGE SHARES PUBLIC LIMITED COMPANY - 3X LONG US TECH 100 ETP ETF Leverage Shares Public Limited Company - 3x Long US Tech 100 ETP
-.--%0.98% 2 M€
12345

Company Profile

Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (99.5%): for the treatment of HIV (68.5% of net sales), oncology diseases (11.5%), hepatitis B virus (10.6%), Ebola virus (6.3%) and other (3.1%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (0.5%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (71.6%), Europe (16.1%) and other (12.3%).
Employees
17,600
Sector
Pharmaceuticals
Calendar
04-22 - Q1 2026 Earnings Release (Projected)
More about the company

Income Statement and Estimates

More financial data

Ratings

Trader

Trader

This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Investor

Investor

This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Global

Global

This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.

Quality

Quality

This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.

ESG MSCI

ESG MSCI

The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.

AAA
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
151.81USD
Average target price
151.12USD
Spread / Average Target
-0.46%
Consensus
EPS Estimates
Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. GILD Stock
  4. ETFs Gilead Sciences, Inc.

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States
United-States
Canada
Canada

MIDDLE EAST

Saudi Arabia
Saudi Arabia
United Arab Emirates
United Arab Emirates

EUROPE

France
France
Deutschland
Deutschland
Suisse
Suisse
Schweiz
Schweiz
Italia
Italia
Österreich
Österreich
België
België
Nederland
Nederland
España
España
Sverige
Sverige
United Kingdom
United Kingdom

APAC

Australia
Australia
India
India
Hong Kong
Hong Kong
United States

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition